APVO News and Press, Aptevo Therapeutics Inc. From 03/25/20

Advances Dose-Escalation Phase 1/1b Study of APVO436 for Treatment of Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome Reports Preliminary Evidence of Clinical Activity of APVO436; Dosing in Cohort 6 to Begin Shortly Achieves Record Annual IXINITY ® Net Reve...

Trial Advancing on Schedule with Dosing in Cohort 6 Set to Begin Shortly; Dose Levels Now Entering Potential Therapeutic Range No Evidence of Dose-Limiting Toxicities Observed in Cohort 5 No Evidence of Drug-Induced Anti-Drug Antibodies Observed to Date SEATTLE, WA / ACCESS...

Transforms Aptevo into a ‘Pure Play' Biotechnology Company Focused on the Development of Proprietary ADAPTIR™ Bispecific Antibody Therapeutics Strengthens Aptevo's Financial Position; Eliminates MidCap Debt Obligation; Provides Immediate Non-Dilutive Capital Extending ...

Acquisition Expected to be Immediately Accretive to Adjusted EBITDA 1 Announces US$20 Million Credit Facility with MidCap Financial TORONTO and CHICAGO and MONTREAL, Feb. 28, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (“ Medexus ” or the “ Company &...

APVO436 is the Latest Investigational AML Therapeutic to be Selected for Participation in the Study; Aptevo Joins Industry Leaders, Bristol-Myers Squib (formerly Celgene) Alexion Pharmaceuticals, Gilead Sciences, Takeda Oncology, Agios Pharmaceuticals, Astellas Pharma and Boehringer Ingelhei...

SEATTLE, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to APVO...

Preclinical Data Show That ALG.APV-527 is Well Tolerated with Repeated Dosing Preliminary in vivo Data Show that ALG.APV-527 has Potent Anti-tumor Activity and Induces an Immunological Memory Response SEATTLE and LUND, Sweden, Nov. 08, 2019 (GLOBE NEWSWIRE) -- ...

Aptevo Therapeutics (NASDAQ: APVO ): Q3 GAAP EPS of -$0.23 beats by $0.01 . More news on: Aptevo Therapeutics Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more ...

Reports Record Net Revenue for IXINITY;  Achieves 55% Increase in Year-over-Year Quarterly Net Revenue Advances APVO436 Phase 1/1b Clinical Study in AML/MDS SEATTLE, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on...

Several days ago, Aptevo Therapeutics ( APVO ) provided a corporate and pipeline update that surprised me (and I don't get surprised easily). To begin with, the company's hemophilia B drug IXINITY will do about $9M in revenue for Q3'19. This is a very important milestone for the company,...